Physician profile
Evan Shlofmitz
NPI 1639494479
$950,744.63
in general payments reported to CMS, 2019-2025
44 companies · $221K in 2025
The $221K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $25K · 2021: $116K · 2022: $187K · 2023: $184K · 2024: $194K · 2025: $221K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $349K · Consulting Fee: $105K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $55K · Honoraria: $36K · Travel and Lodging: $28K · Food and Beverage: $23K · Long Term Medical Supply Or Device Loan: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $348,616.94 |
| Consulting Fee | $105,288.55 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $55,300.00 |
| Honoraria | $36,260.00 |
| Travel and Lodging | $27,793.36 |
| Food and Beverage | $22,964.19 |
| Long Term Medical Supply Or Device Loan | $2,282.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $236,567.56 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $150,200.42 | 2020-2024 | Xarelto |
| Abbott Laboratories | $130,030.11 | 2019-2025 | Optis, Ultreon, Coroflow |
| Shockwave Medical, INC | $113,374.70 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $99,932.81 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $45,969.18 | 2021-2025 | (9520) Igt Devices Undivided, Igt Devices Undivided, US Eq Undivided |
| Boston Scientific Corporation | $41,779.67 | 2019-2025 | General - Vascular Access, Avvigo Guidance System, Rotapro |
| Lexicon Pharmaceuticals, INC. | $36,487.56 | 2024 | Inpefa |
| Heartflow, INC. | $25,589.53 | 2024-2025 | |
| Medtronic Vascular, INC. | $12,843.27 | 2019-2020 | |
| Medtronic, INC. | $11,099.93 | 2021-2025 | Symplicity G3, Corevalve Evolut R, Mycarelink |
| Chiesi USA, INC. | $10,234.99 | 2022-2023 | Kengreal |
| Cardiovascular Systems INC. | $6,080.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $5,819.29 | 2022-2024 | Farxiga |
| Acist Medical Systems, INC. | $5,520.92 | 2021-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opsens INC. | $4,000.00 | 2020-2023 | Savvywire |
| Janssen Global Services, LLC | $3,720.00 | 2022 | |
| Gentuity, LLC | $2,982.26 | 2024-2025 | Gentuity Hf-Oct Imaging System, Vis-Rx Prime, Vis-Rx |
| Terumo Medical Corporation | $2,430.02 | 2023-2025 | Glidesheath Slender, Metacross Otw, Heartrail |
| Spectrawave, INC | $1,829.56 | 2023-2025 | Hypervue Imaging System, Starlight Imaging Catheter, X1-Ffr |
| Cordis US Corp. | $541.67 | 2023 | Mynx Control |
| Cathworks, INC. | $467.88 | 2021-2024 | Ffrangio |
| Esperion Therapeutics, INC. | $458.82 | 2021-2025 | Nexletol, Nexlizet |
| Neovasc Medical INC | $427.98 | 2021 | |
| Penumbra, INC. | $366.03 | 2022 | |
| Biotronik INC. | $360.11 | 2022-2025 | Biomonitor, Acticor 7 Vr-T Dx, Nhancer Rx |
| Cardiva Medical, INC. | $261.29 | 2024-2025 | Savvywire, Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs |
| Abiomed | $202.84 | 2025 | |
| Cvrx, INC. | $139.80 | 2024 | Barostim Neo System |
| Inari Medical, INC. | $122.44 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.21 | 2020 | |
| Recor Medical INC | $118.47 | 2025 | Paradise Ultrasound Renal Denervation System |
| Arrow International, INC. | $118.09 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $87.80 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $84.40 | 2023-2025 | Eliquis, Camzyos |
| Kestra Medical Technology Services, INC. | $77.52 | 2022-2023 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $72.32 | 2023-2024 | |
| Cardinal Health 200 LLC | $56.64 | 2019 | |
| Celonova Biosciences, INC. | $49.20 | 2020 | |
| Impulse Dynamics (USA) INC. | $38.09 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $29.63 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.41 | 2025 | |
| Edwards Lifesciences Corporation | $24.22 | 2025 | Sapien 3 Ultra Resilia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Shlofmitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.